Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets

[1]  Yin Li,et al.  Relationship of Epidermal Growth Factor Receptor Expression with Clinical Symptoms and Metastasis of Invasive Breast Cancer. , 2018, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[2]  R. Weigel,et al.  A novel HER2 gene body enhancer contributes to HER2 expression , 2017, Oncogene.

[3]  C. Sotiriou,et al.  CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. , 2017, Cancer research.

[4]  R. Shiekhattar,et al.  Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs , 2017, Genes & development.

[5]  S. Noguchi,et al.  A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells , 2017, Breast Cancer Research and Treatment.

[6]  E. Domany,et al.  Coordinated Pulses of mRNA and of Protein Translation or Degradation Produce EGF-Induced Protein Bursts. , 2017, Cell reports.

[7]  J. Vadgama,et al.  RETRACTED ARTICLE: A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells , 2017, Breast Cancer Research and Treatment.

[8]  M. Buendia,et al.  LIM-Only Protein FHL2 Is a Negative Regulator of Transforming Growth Factor β1 Expression , 2017, Molecular and Cellular Biology.

[9]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[10]  Wen-juan Wang,et al.  Overexpression of ubiquitin carboxyl terminal hydrolase‐L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway , 2016, Molecular carcinogenesis.

[11]  R. Huddart,et al.  Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Fan Liu,et al.  Beyond transcription factors: how oncogenic signalling reshapes the epigenetic landscape , 2016, Nature Reviews Cancer.

[13]  D. Braun,et al.  Wnt9A Induction Linked to Suppression of Human Colorectal Cancer Cell Proliferation , 2016, International journal of molecular sciences.

[14]  G. Hortobagyi,et al.  Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer , 2016, Oncotarget.

[15]  Matthias Gieseke,et al.  Poly-ε-caprolactone Coated and Functionalized Porous Titanium and Magnesium Implants for Enhancing Angiogenesis in Critically Sized Bone Defects , 2015, International journal of molecular sciences.

[16]  A. Vincent-Salomon,et al.  Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis , 2015, Genes & development.

[17]  R. Shiekhattar,et al.  Integrator mediates the biogenesis of enhancer RNAs , 2015, Nature.

[18]  Jie Zhang,et al.  S100 Calcium-Binding Protein A6 Promotes Epithelial-Mesenchymal Transition through β-Catenin in Pancreatic Cancer Cell Line , 2015, PloS one.

[19]  S. Wiemann,et al.  EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer , 2015, Science Signaling.

[20]  David J Weber,et al.  S100 proteins in cancer , 2015, Nature Reviews Cancer.

[21]  M. Pellegrini,et al.  Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. , 2014, Cell host & microbe.

[22]  A. Shilatifard,et al.  Integrator regulates transcriptional initiation and pause release following activation. , 2014, Molecular cell.

[23]  Eytan Domany,et al.  Epidermal Growth-Factor – Induced Transcript Isoform Variation Drives Mammary Cell Migration , 2013, PloS one.

[24]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[25]  E. Paredes-Gamero,et al.  Heparan sulfate mediates trastuzumab effect in breast cancer cells , 2013, BMC Cancer.

[26]  H. Rugo,et al.  Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer , 2013, Breast Cancer Research and Treatment.

[27]  M. J. Kwon,et al.  Emerging Roles of Claudins in Human Cancer , 2013, International journal of molecular sciences.

[28]  M. Blumenberg.  Profiling and metaanalysis of epidermal keratinocytes responses to epidermal growth factor , 2013, BMC Genomics.

[29]  L. Gfrerer,et al.  Distinct requirements for wnt9a and irf6 in extension and integration mechanisms during zebrafish palate morphogenesis , 2013, Development.

[30]  E. López-Bonet,et al.  Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin) , 2012, Cell cycle.

[31]  J. Vadgama,et al.  Expression of Wnt3 Activates Wnt/β-Catenin Pathway and Promotes EMT-like Phenotype in Trastuzumab-Resistant HER2-Overexpressing Breast Cancer Cells , 2012, Molecular Cancer Research.

[32]  V. Blank,et al.  The small MAF transcription factors MAFF, MAFG and MAFK: current knowledge and perspectives. , 2012, Biochimica et biophysica acta.

[33]  Wei Jiang,et al.  Histone H3K27me3 demethylases KDM6A and KDM6B modulate definitive endoderm differentiation from human ESCs by regulating WNT signaling pathway , 2012, Cell Research.

[34]  T. Tan,et al.  DUSPs, to MAP kinases and beyond , 2012, Cell & Bioscience.

[35]  A. Armstrong,et al.  Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Fiszman,et al.  Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer , 2011, International journal of breast cancer.

[37]  Sendurai A Mani,et al.  Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression , 2011, Breast Cancer Research.

[38]  Li-Rong Yu,et al.  Distinct roles of GCN5/PCAF‐mediated H3K9ac and CBP/p300‐mediated H3K18/27ac in nuclear receptor transactivation , 2011, The EMBO journal.

[39]  V. Yang,et al.  Mammalian Krüppel-like factors in health and diseases. , 2010, Physiological reviews.

[40]  P. Fang,et al.  Zebrafish Wnt9a,9b paralog comparisons suggest ancestral roles for Wnt9 in neural, oral-pharyngeal ectoderm and mesendoderm. , 2010, Gene expression patterns : GEP.

[41]  Eran Segal,et al.  EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors , 2010, Science Signaling.

[42]  Jeong Eon Lee,et al.  EGF-induced MMP-9 expression is mediated by the JAK3/ERK pathway, but not by the JAK3/STAT-3 pathway in a SKBR3 breast cancer cell line. , 2009, Cellular signalling.

[43]  S. Jackson,et al.  Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells , 2009, The EMBO journal.

[44]  Ken Matsumoto,et al.  Wnt9a secreted from the walls of hepatic sinusoids is essential for morphogenesis, proliferation, and glycogen accumulation of chick hepatic epithelium. , 2008, Developmental biology.

[45]  M. Los,et al.  Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer , 2007, Biologics : targets & therapy.

[46]  Eytan Domany,et al.  A module of negative feedback regulators defines growth factor signaling , 2007, Nature Genetics.

[47]  C. Hartmann,et al.  Wnt9a signaling is required for joint integrity and regulation of Ihh during chondrogenesis , 2006, Development.

[48]  L. Topol,et al.  Wnt/β-catenin signaling is sufficient and necessary for synovial joint formation , 2004 .

[49]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[50]  A. Berezov,et al.  HER2/Neu: mechanisms of dimerization/oligomerization , 2000, Oncogene.

[51]  J. Szöllősi,et al.  Complexity of signal transduction mediated by ErbB2: Clues to the potential of receptor-targeted cancer therapy , 1999, Pathology & Oncology Research.

[52]  L. E. Johannessen,et al.  Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. , 1999, The Biochemical journal.

[53]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[54]  Y. Imai,et al.  Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long-term tissue culture. , 1982, Cancer research.

[55]  G. Thompson,et al.  Sexual dimorphism in hand and wrist ossification. , 1973, Growth.

[56]  Sigrid A. Langhans,et al.  Epidermal growth factor signaling in transformed cells. , 2015, International review of cell and molecular biology.

[57]  B. Garcia,et al.  Proteomic Interrogation of Human Chromatin Protein States , 2014 .

[58]  Carlos L Arteaga,et al.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. , 2012, Critical reviews in oncogenesis.

[59]  Y. Yarden,et al.  The basic biology of HER2. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.